Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
33 hedge funds and large institutions have $3.75M invested in Finch Therapeutics Group, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 7 closing their positions.
18% less funds holding
Funds holding: 40 → 33 (-7)
18% less capital invested
Capital invested by funds: $4.6M → $3.75M (-$848K)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$442K |
| 2 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$3.09K |
| 3 |
BlackRock
New York
|
+$902 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
TRB Advisors
New York
|
-$274K |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$108K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$78.8K |
| 4 |
Renaissance Technologies
New York
|
-$13.2K |
| 5 |
Millennium Management
New York
|
-$11.3K |
FNCH Hedge Fund Activity: Q1 2023 in Review
33 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q1 2023, worth a combined $3.75M — down 18% from $4.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FNCH and 0 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Baupost Group, adding an estimated $442K. The largest seller was TRB Advisors, exiting entirely with an estimated $274K sold.
- 33 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q1 2023, down from 40 in Q4 2022.
- Funds reported $3.75M of Finch Therapeutics Group, Inc. Common Stock stock for Q1 2023, down 18% quarter-over-quarter.
- 0 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q1 2023 and 7 closed out, a net change of -7 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q1 2023 was Baupost Group, an estimated $442K added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q1 2023 was TRB Advisors, an estimated $274K sold.
Based on aggregated 13F filings for Q1 2023.